Eli Lilly and Company Interest Expense 2011-2026 | LLY

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Eli Lilly and Company

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-14.3 M	340 M	360 M	401 M	242 M	225 M	185 M	161 M	149 M	160 M	178 M	186 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
401 M	-14.3 M	214 M

Quarterly Interest Expense Eli Lilly and Company

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-101 M	-3.5 M	-20.9 M	-7.8 M	28.8 M	-100 K	-13.2 M	103 M	-	81.5 M	81.2 M	84.9 M	-	83.6 M	86.9 M	87.8 M	-	89.6 M	88.3 M	92.5 M	-	107 M	111 M	86.5 M	-	60.8 M	63.3 M	61.2 M	-	61.9 M	53.6 M	46.6 M	-	47.2 M	43.2 M	43.4 M	-	39.3 M	36.8 M	40.9 M	-	38.1 M	35.5 M	37.8 M	-	39.8 M	40.3 M	40.3 M	-	47 M	43 M	45.3 M	-	45 M	45.1 M	45.8 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
111 M	-101 M	49.3 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
BioNTech SE BNTX	14.2 M	$ 94.83	-0.7 %	$ 27.2 B	Germany
INmune Bio INMB	2.28 M	$ 1.54	0.01 %	$ 38.1 M	USA
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.48	0.58 %	$ 3.73 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 3.13	0.55 %	$ 651 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.46	-1.14 %	$ 5.7 M	Israel
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Exelixis EXEL	-198 K	$ 48.55	9.3 %	$ 13.2 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 24.03	2.6 %	$ 3.06 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
CRISPR Therapeutics AG CRSP	86.6 M	$ 54.84	4.7 %	$ 4.93 B	Schweiz
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.73	5.18 %	$ 460 M	Britain
Fortress Biotech FBIO	17.6 M	$ 2.57	4.27 %	$ 71.7 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA